PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.21%
Positive EBIT growth while AXSM is negative. John Neff might see a substantial edge in operational management.
40.44%
Positive operating income growth while AXSM is negative. John Neff might view this as a competitive edge in operations.
42.50%
Positive net income growth while AXSM is negative. John Neff might see a big relative performance advantage.
40.54%
Positive EPS growth while AXSM is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
40.54%
Positive diluted EPS growth while AXSM is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.40%
Share reduction more than 1.5x AXSM's 0.83%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.40%
Diluted share reduction more than 1.5x AXSM's 0.83%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
51.97%
Positive OCF growth while AXSM is negative. John Neff would see this as a clear operational advantage vs. the competitor.
51.97%
Positive FCF growth while AXSM is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while AXSM stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.95%
Positive long-term OCF/share growth while AXSM is negative. John Neff would see a structural advantage in sustained cash generation.
79.78%
Positive OCF/share growth while AXSM is negative. John Neff might see a comparative advantage in operational cash viability.
21.40%
3Y OCF/share CAGR at 50-75% of AXSM's 29.32%. Martin Whitman would suspect weaker recent execution or product competitiveness.
95.64%
Positive 10Y CAGR while AXSM is negative. John Neff might see a substantial advantage in bottom-line trajectory.
74.54%
Positive 5Y CAGR while AXSM is negative. John Neff might view this as a strong mid-term relative advantage.
42.66%
Positive short-term CAGR while AXSM is negative. John Neff would see a clear advantage in near-term profit trajectory.
160.55%
Below 50% of AXSM's 566.43%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
2.24%
Below 50% of AXSM's 123.21%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-69.25%
Negative 3Y equity/share growth while AXSM is at 110.84%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 5Y dividend/share CAGR while AXSM stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.35%
Negative asset growth while AXSM invests at 1.25%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-14.61%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.07%
We’re deleveraging while AXSM stands at 0.34%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-50.78%
Our R&D shrinks while AXSM invests at 21.72%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-4.70%
We cut SG&A while AXSM invests at 18.53%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.